AR022252A1 - Composicion de administracion oral. - Google Patents
Composicion de administracion oral.Info
- Publication number
- AR022252A1 AR022252A1 ARP000100109A ARP000100109A AR022252A1 AR 022252 A1 AR022252 A1 AR 022252A1 AR P000100109 A ARP000100109 A AR P000100109A AR P000100109 A ARP000100109 A AR P000100109A AR 022252 A1 AR022252 A1 AR 022252A1
- Authority
- AR
- Argentina
- Prior art keywords
- oral administration
- administration composition
- physiologically tolerable
- tolerable salt
- treble
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerable del mismo, un alfa-agonista o unasal fisiologicamente tolerable del mismo, conjuntamente con lactosa o fosfato monoácido cálcico,con o sin otros excipientes farmacéuticos, así como su uso enestados álgicos de mediana intensidad hasta agudos severos o cronicos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19901684 | 1999-01-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR022252A1 true AR022252A1 (es) | 2002-09-04 |
Family
ID=7894563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000100109A AR022252A1 (es) | 1999-01-18 | 2000-01-11 | Composicion de administracion oral. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20020044966A1 (es) |
EP (1) | EP1143936A2 (es) |
JP (1) | JP2002534458A (es) |
AR (1) | AR022252A1 (es) |
AU (1) | AU772886B2 (es) |
BR (1) | BR0000578A (es) |
CA (1) | CA2359273A1 (es) |
CO (1) | CO5160243A1 (es) |
HU (2) | HUP0105043A3 (es) |
NO (2) | NO20000225D0 (es) |
NZ (1) | NZ513501A (es) |
PE (1) | PE20001396A1 (es) |
SK (1) | SK10012001A3 (es) |
UY (1) | UY25936A1 (es) |
WO (1) | WO2000041681A2 (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107213128A (zh) | 1999-10-29 | 2017-09-29 | 欧罗赛铁克股份有限公司 | 控释氢可酮制剂 |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
CA2424021A1 (en) * | 2000-09-29 | 2002-04-04 | Board Of Trustees Operating Michigan State University | Catecholamine compositions and uses thereof |
KR100968128B1 (ko) | 2000-10-30 | 2010-07-06 | 유로-셀티크 소시에떼 아노뉨 | 서방성 하이드로코돈 제형 |
US6287599B1 (en) * | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
EP1395243A2 (en) * | 2001-05-31 | 2004-03-10 | SkyePharma Inc. | Encapsulation of nanosuspensions in liposomes and microspheres |
EP1414458B1 (en) * | 2001-07-06 | 2007-04-11 | Endo Pharmaceuticals Inc. | Oral administration of 6-hydroxy-oxymorphone for use as an analgesic |
US8329216B2 (en) * | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
US20030091635A1 (en) * | 2001-09-26 | 2003-05-15 | Baichwal Anand R. | Opioid formulations having reduced potential for abuse |
US7854230B2 (en) * | 2001-10-22 | 2010-12-21 | O.R. Solutions, Inc. | Heated medical instrument stand with surgical drape and method of detecting fluid and leaks in the stand tray |
US8487002B2 (en) * | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
TWI319713B (en) * | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
US7648982B2 (en) * | 2003-02-28 | 2010-01-19 | Ym Biosciences Inc. | Opioid delivery system |
US7648981B2 (en) * | 2003-02-28 | 2010-01-19 | Ym Biosciences Inc. | Opioid delivery system |
US20060172006A1 (en) * | 2003-10-10 | 2006-08-03 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour clinical efficacy |
US20050100594A1 (en) * | 2003-11-12 | 2005-05-12 | Nilendu Sen | Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor |
DE102005013726A1 (de) * | 2005-03-22 | 2006-09-28 | Grünenthal GmbH | Transdermale therapeutische Systeme mit verbesserter Verträglichkeit |
US7485323B2 (en) * | 2005-05-31 | 2009-02-03 | Gelita Ag | Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions |
NZ565649A (en) * | 2005-07-28 | 2011-03-31 | Shire Llc | Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily |
EP1931346B1 (en) * | 2005-09-09 | 2012-07-18 | Angelini Labopharm, LLC | Trazodone composition for once a day administration |
US20070212414A1 (en) * | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
US20080069891A1 (en) * | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
MX2009013384A (es) | 2007-06-08 | 2010-01-25 | Addrenex Pharmaceuticals Inc | Formulacion de liberacion extendida, y metodo para tratar disregulacion adrenergica. |
US20100172991A1 (en) * | 2007-06-08 | 2010-07-08 | Henry Joseph Horacek | Extended Release Formulation and Methods of Treating Adrenergic Dysregulation |
US20090124650A1 (en) * | 2007-06-21 | 2009-05-14 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol |
WO2009130715A1 (en) * | 2008-04-25 | 2009-10-29 | Cadila Healtcare Limited | Rapidly disintegrating oral compositions of tramadol |
WO2009158477A1 (en) * | 2008-06-25 | 2009-12-30 | Us Worldmeds Llc | Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery |
CN102196819B (zh) * | 2008-10-30 | 2013-01-30 | 国立大学法人冈山大学 | 局部麻醉用组合物 |
MX348361B (es) * | 2009-12-17 | 2017-06-07 | Cima Labs Inc | Formulaciones resistentes al abuso. |
EP2568977A1 (en) | 2010-05-11 | 2013-03-20 | Cima Labs Inc. | Alcohol-resistant metoprolol-containing extended- release oral dosage forms |
CA2991217C (en) | 2010-12-22 | 2020-06-09 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
WO2013052770A1 (en) | 2011-10-05 | 2013-04-11 | Sanders Jennifer L | Methods and compositions for treating foot or hand pain |
US20130096170A1 (en) | 2011-10-14 | 2013-04-18 | Hospira, Inc. | Methods of treating pediatric patients using dexmedetomidine |
US8242158B1 (en) | 2012-01-04 | 2012-08-14 | Hospira, Inc. | Dexmedetomidine premix formulation |
TWI629066B (zh) | 2013-10-07 | 2018-07-11 | 帝國製藥美國股份有限公司 | 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物 |
EP3054932B1 (en) | 2013-10-07 | 2020-12-09 | Teikoku Pharma USA, Inc. | Dexmedetomidine transdermal delivery devices and methods for using the same |
CN105764496B (zh) | 2013-10-07 | 2020-09-25 | 帝国制药美国公司 | 用于经皮递送非镇静量的右旋美托咪啶的方法和组合物 |
US20150118300A1 (en) | 2013-10-31 | 2015-04-30 | Cima Labs Inc. | Immediate Release Abuse-Deterrent Granulated Dosage Forms |
US20220062200A1 (en) | 2019-05-07 | 2022-03-03 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
US11324707B2 (en) | 2019-05-07 | 2022-05-10 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
CN112494486B (zh) * | 2020-12-07 | 2022-01-21 | 深圳善康医疗健康产业有限公司 | 一种用于减轻或消除阿片戒断综合症的药物组合物及应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946848A (en) * | 1985-10-29 | 1990-08-07 | Baker Cumins Dermatologicals, Inc. | Method of treating pruritus with nalmefene and clonidine |
PT99629A (pt) * | 1991-11-28 | 1993-05-31 | Antonio Feria Reis Valle | Metodo de desintoxicacao de opiaceos |
US5635204A (en) * | 1994-03-04 | 1997-06-03 | Montefiore Medical Center | Method for transdermal induction of anesthesia, analgesia or sedation |
DE19758564A1 (de) * | 1997-11-11 | 1999-08-26 | Gruenenthal Gmbh | Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung |
-
2000
- 2000-01-06 PE PE2000000011A patent/PE20001396A1/es not_active Application Discontinuation
- 2000-01-11 AR ARP000100109A patent/AR022252A1/es unknown
- 2000-01-17 CA CA002359273A patent/CA2359273A1/en not_active Abandoned
- 2000-01-17 EP EP00901108A patent/EP1143936A2/de not_active Withdrawn
- 2000-01-17 CO CO00002026A patent/CO5160243A1/es unknown
- 2000-01-17 JP JP2000593293A patent/JP2002534458A/ja not_active Withdrawn
- 2000-01-17 HU HU0105043A patent/HUP0105043A3/hu unknown
- 2000-01-17 WO PCT/EP2000/000318 patent/WO2000041681A2/de active IP Right Grant
- 2000-01-17 UY UY25936A patent/UY25936A1/es not_active Application Discontinuation
- 2000-01-17 HU HU0000139A patent/HU0000139D0/hu unknown
- 2000-01-17 AU AU21090/00A patent/AU772886B2/en not_active Ceased
- 2000-01-17 SK SK1001-2001A patent/SK10012001A3/sk unknown
- 2000-01-17 NO NO20000225A patent/NO20000225D0/no unknown
- 2000-01-17 NZ NZ513501A patent/NZ513501A/en unknown
- 2000-01-17 BR BR0000578-9A patent/BR0000578A/pt not_active IP Right Cessation
-
2001
- 2001-07-03 NO NO20013302A patent/NO20013302D0/no not_active Application Discontinuation
- 2001-07-18 US US09/907,447 patent/US20020044966A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20020044966A1 (en) | 2002-04-18 |
JP2002534458A (ja) | 2002-10-15 |
AU2109000A (en) | 2000-08-01 |
NO20013302L (no) | 2001-07-03 |
WO2000041681A3 (de) | 2000-12-07 |
CO5160243A1 (es) | 2002-05-30 |
CA2359273A1 (en) | 2000-07-20 |
SK10012001A3 (sk) | 2002-01-07 |
HUP0105043A3 (en) | 2005-06-28 |
EP1143936A2 (de) | 2001-10-17 |
NO20000225D0 (no) | 2000-01-17 |
PE20001396A1 (es) | 2000-12-23 |
NZ513501A (en) | 2003-11-28 |
BR0000578A (pt) | 2001-08-14 |
NO20013302D0 (no) | 2001-07-03 |
HU0000139D0 (en) | 2000-03-28 |
HUP0105043A2 (en) | 2002-06-29 |
UY25936A1 (es) | 2001-07-31 |
AU772886B2 (en) | 2004-05-13 |
WO2000041681A2 (de) | 2000-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR022252A1 (es) | Composicion de administracion oral. | |
CL2009001682A1 (es) | Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00). | |
ES2181055T3 (es) | Formulaciones galenicas que contienen antagonistas de opiaceos. | |
BR0015188A (pt) | Composições farmacêuticas | |
CR6458A (es) | Composiciones de valdecoxib | |
CY1105120T1 (el) | Η αντιμετωπιση αναπνευστικων νοσων | |
EE200300033A (et) | Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon | |
ATE286057T1 (de) | Pharmazeutische zubereitungen enthaltend clavulansäure | |
CY1108532T1 (el) | Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων | |
TW200505498A (en) | Sugar-free oral transmucosal solid dosage forms and uses thereof | |
IT1276689B1 (it) | Forma farmaceutica solida ad uso orale | |
EA199800946A1 (ru) | Концентрированный препарат антител | |
AR032293A1 (es) | Estuche farmaceutico | |
DK1317419T3 (da) | Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler | |
BR9810495A (pt) | Composição farmacêutica | |
AR004700A1 (es) | 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento | |
DE50005529D1 (de) | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac | |
ATE499939T1 (de) | Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend | |
BR0112847A (pt) | Uso de uma forma de dosagem sólida | |
EA200300427A1 (ru) | Противоопухолевая терапия, включающая производные дистамицина | |
DE69921486D1 (de) | Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren | |
CY1108785T1 (el) | Σταθερη φαρμακευτικη γελη diclofenac na | |
MA26788A1 (fr) | COMPOSITIONS PHARMACEUTIQUES DESTINÉES à L'ADMINISTRATION PAR VOIE ORALE DE PHLOROGLUCINOL ET LEUR PRÉPARATION | |
CY1107227T1 (el) | Θεραπεια αυτοανοσων νοσων με εκχυλισμα αμερικανικου γκινσενγκ | |
AR043016A2 (es) | Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |